To include your compound in the COVID-19 Resource Center, submit it here.

Teva's subcutaneous reslizumab misses in Phase III for eosinophilic asthma

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) reported top-line data from a Phase III trial in 468 patients with uncontrolled asthma and elevated blood eosinophils of of

Read the full 279 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE